REG - BioPharma Credit PLC - Dividend Declaration

Biopharma CreditAnnouncement

Today 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260422:nRSV5421Ba&default-theme=true

RNS Number : 5421B  BioPharma Credit PLC  22 April 2026

22 April 2026

 

BIOPHARMA CREDIT PLC

("BIOPHARMA CREDIT" OR THE "COMPANY")

DIVIDEND DECLARATION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor,
is pleased to declare an interim dividend in respect of the quarterly
financial period ending 31 March 2026 of 1.75 cents per share, payable
on 29 May 2026 to ordinary shareholders on the register as at 1 May 2026.
The ex-dividend date will be 30 April 2026.

The Company's investment objective is to generate long-term shareholder
returns, predominantly in the form of sustainable income distributions from
its investments in the life sciences industry. The Company currently pays, and
continues to target, a 7-cent base annual dividend per ordinary share in four
quarterly payments of 1.75 cents per share. Typically, these have been
supplemented by excess income in the form of special dividend distributions in
Q4 and in some years, Q3 and Q4, where the Board determines that it is
appropriate and able to do so (noting the requirement to pay out substantially
all income to maintain the Company's investment trust status).

Dividends in recent years:

 Financial year (ending 31 December)  Amount (US cents)
 2025                                  9.95
 2024                                 10.18
 2023                                 10.21

By way of reference, the Company's shares traded as of (21 April 2026) at a
price of 93.60 cents.

The default payment for dividends is in US dollars. However, shareholders can
elect to have dividends paid in sterling (GBP) and the option to elect a
sterling dividend payment for this dividend will be available to shareholders
until 1 May 2026 (being the "Election Date").

The Company has chosen to designate the entire amount of this interim dividend
as an interest distribution. Shareholders in receipt of such a dividend will
be treated for UK tax purposes as though they have received a payment of
interest. This will result in a reduction in the corporation tax payable by
the Company.

A copy of the Dividend Currency Election Form, which should be sent to MUFG
Corporate Markets, 19(th) Floor, 51 Lime Street, London EC3M 7DQ when
completed, will be available on the Company's website
at www.bpcruk.com/investor-materials
(http://www.bpcruk.com/investor-materials) . CREST shareholders must elect via
CREST.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DIVITMATMTMTBPF



            Copyright 2019 Regulatory News Service, all rights reserved